Treatment with lipoxin A4 improves influenza A infection outcome, induces macrophage reprogramming, anti-inflammatory and pro-resolutive responses-Reference-Cited by-同舟云学术

Treatment with lipoxin A4 improves influenza A infection outcome, induces macrophage reprogramming, anti-inflammatory and pro-resolutive responses

Published:2024-08-30 Issue: Volume: Page:
ISSN:1023-3830
Container-title:Inflammation Research
language:en
Short-container-title:Inflamm. Res.

Author:

Rago Flavia,Melo Eliza Mathias,Miller Leigh M.,Duray Alexis M.,Batista Felix Franciel,Vago Juliana Priscila,de Faria Gonçalves Ana Paula,Angelo Ana Luiza Pessoa Mendonça,Cassali Geovanni D.,de Gaetano Monica,Brennan Eoin,Owen Benjamin,Guiry Patrick,Godson Catherine,Alcorn John F.,Teixeira Mauro Martins

Funder

National Institutes of Health

Conselho Nacional de Desenvolvimento Científico eTecnológico

Fundação de Amparo à Pesquisa do Estado de Minas Gerais

The National Institute of Science and Technology in dengue and host-microbial interactions

Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior - Brasil

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00011-024-01939-9.pdf

Reference94 articles.

1. Hutchinson EC, Fodor E. Transport of the influenza virus genome from nucleus to nucleus. Viruses. 2013;5:2424–46.

2. Akin L, Gözel MG. Understanding dynamics of pandemics. Turkish J Med Sci. 2020;50:515–9.

3. Tavares LP, Teixeira MM, Garcia CC. The inflammatory response triggered by Influenza virus: a two edged sword. Inflamm Res. 2017;66:283–302.

4. WHO. Influenza (Seasonal). Available at: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).

5. Batool S, Chokkakula S, Song M-S. Influenza treatment: limitations of antiviral therapy and advantages of drug combination therapy. Microorganisms. 2023;11:183.